109 related articles for article (PubMed ID: 29793671)
1. [Cardiovascular consequences of chronic kidney disease, impact of modulation of epoxyeicosatrienoic acids].
Hamzaoui M; Guerrot D; Djerada Z; Duflot T; Richard V; Bellien J
Ann Cardiol Angeiol (Paris); 2018 Jun; 67(3):141-148. PubMed ID: 29793671
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?
Bellien J; Joannides R; Richard V; Thuillez C
Pharmacol Ther; 2011 Jul; 131(1):1-17. PubMed ID: 21514320
[TBL] [Abstract][Full Text] [Related]
3. Linking an insect enzyme to hypertension: angiotensin II-epoxide hydrolase interactions.
Ai D; Shyy JY; Zhu Y
Kidney Int; 2010 Jan; 77(2):88-92. PubMed ID: 19847158
[TBL] [Abstract][Full Text] [Related]
4. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.
Duflot T; Roche C; Lamoureux F; Guerrot D; Bellien J
Expert Opin Drug Discov; 2014 Mar; 9(3):229-43. PubMed ID: 24490654
[TBL] [Abstract][Full Text] [Related]
5. Soluble epoxide hydrolase: A potential target for metabolic diseases.
He J; Wang C; Zhu Y; Ai D
J Diabetes; 2016 May; 8(3):305-13. PubMed ID: 26621325
[TBL] [Abstract][Full Text] [Related]
6. Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.
Imig JD
Adv Pharmacol; 2016; 77():105-41. PubMed ID: 27451096
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of epoxyeicosatrienoic acids in coronary vascular function.
Larsen BT; Gutterman DD; Hatoum OA
Eur J Clin Invest; 2006 May; 36(5):293-300. PubMed ID: 16634832
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
[TBL] [Abstract][Full Text] [Related]
9. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
10. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
Ni GH; Chen JF; Chen XP; Yang TL
Pharmazie; 2011 Mar; 66(3):153-7. PubMed ID: 21553642
[TBL] [Abstract][Full Text] [Related]
11. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.
Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M
Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314
[TBL] [Abstract][Full Text] [Related]
12. Palmitoylethanolamide treatment reduces blood pressure in spontaneously hypertensive rats: involvement of cytochrome p450-derived eicosanoids and renin angiotensin system.
Mattace Raso G; Pirozzi C; d'Emmanuele di Villa Bianca R; Simeoli R; Santoro A; Lama A; Di Guida F; Russo R; De Caro C; Sorrentino R; Calignano A; Meli R
PLoS One; 2015; 10(5):e0123602. PubMed ID: 25951330
[TBL] [Abstract][Full Text] [Related]
13. Vascular localization of soluble epoxide hydrolase in the human kidney.
Yu Z; Davis BB; Morisseau C; Hammock BD; Olson JL; Kroetz DL; Weiss RH
Am J Physiol Renal Physiol; 2004 Apr; 286(4):F720-6. PubMed ID: 14665429
[TBL] [Abstract][Full Text] [Related]
14. Eicosanoids and renal damage in cardiometabolic syndrome.
Imig JD
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):165-74. PubMed ID: 18248310
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Červenka L; Melenovský V; Husková Z; Škaroupková P; Nishiyama A; Sadowski J
Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):795-807. PubMed ID: 25969338
[TBL] [Abstract][Full Text] [Related]
16. [Soluble epoxide hydrolase and lipid metabolism].
Ma XX; Liu Y; Zhu Y
Sheng Li Ke Xue Jin Zhan; 2010 Aug; 41(4):267-71. PubMed ID: 21416942
[TBL] [Abstract][Full Text] [Related]
17. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
18. Contribution of volume overload to progression of cardiovascular disease in a rat model of chronic kidney disease.
Mahmoud MM; Shamseldeen AM; Rashed LA; Fares AE; Shamaa A; Gharib DM
Can J Physiol Pharmacol; 2018 Dec; 96(12):1197-1208. PubMed ID: 30079760
[TBL] [Abstract][Full Text] [Related]
19. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
20. Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Luther JM; Brown NJ
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():2-7. PubMed ID: 27448715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
